Antisense therapy for cancer

被引：288
作者：
Gleave, ME
Monia, BP
机构：
[1] Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC V5Z 355, Canada
[2] Univ British Columbia, Div Urol, Vancouver, BC V5Z 355, Canada
[3] ISIS Pharmaceut, Carlsbad, CA 92008 USA
来源：
NATURE REVIEWS CANCER | 2005年 / 5卷 / 06期
关键词：
D O I：
10.1038/nrc1631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Improved understanding of the molecular mechanisms that mediate cancer progression and therapeutic resistance has identified many therapeutic gene targets that regulate apoptosis, proliferation and cell signalling. Antisense oligonucleotides offer one approach to target genes involved in cancer progression, especially those that are not amenable to small-molecule or antibody inhibition. Better chemical modifications of antisense oligonucleotides increase resistance to nuclease digestion, prolong tissue half-lives and improve scheduling. Indeed, recent clinical trials confirm the ability of this class of drugs to significantly suppress target-gene expression. The current status and future directions of several antisense drugs that have potential clinical use in cancer are reviewed.
引用
收藏
页码：468 / 479
页数：12
相关论文
共 174 条
[1]  
Adjei AA, 2003, CLIN CANCER RES, V9, P115
[2]   Functional analysis of the human MCL-1 gene [J].
Akgul, C ;
Turner, PC ;
White, MRH ;
Edwards, SW .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (04) :684-691
[3]   Survivin, versatile modulation of cell division and apoptosis in cancer [J].
Altieri, DC .
ONCOGENE, 2003, 22 (53) :8581-8589
[4]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[5]   Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma [J].
Ansell, SM ;
Arendt, BK ;
Grote, DM ;
Jelinek, DF ;
Novak, AJ ;
Wellik, LE ;
Remstein, ED ;
Bennett, CF ;
Fielding, A .
LEUKEMIA, 2004, 18 (03) :616-623
[6]  
Arts HJG, 1999, INT J CANCER, V84, P234, DOI 10.1002/(SICI)1097-0215(19990621)84:3<234::AID-IJC6>3.0.CO
[7]  
2-9
[8]   MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain [J].
Bae, J ;
Leo, CP ;
Hsu, SY ;
Hsueh, AJW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) :25255-25261
[9]   Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to trastuzumab [J].
Biroccio, A ;
D'Angelo, C ;
Jansen, B ;
Cleave, ME ;
Zupi, G .
JOURNAL OF CELLULAR PHYSIOLOGY, 2005, 204 (02) :463-469
[10]   Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies [J].
Bishop, MR ;
Iversen, PL ;
Bayever, E ;
Sharp, JG ;
Greiner, TC ;
Copple, BL ;
Ruddon, R ;
Zon, G ;
Spinolo, J ;
Arneson, M ;
Armitage, JO ;
Kessinger, A .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1320-1326
12345678910